

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg

This is the group's first NoC approval in Canada

Ahmedabad, India, August 7, 2025

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 & 1 mg. This is the group's first NOC approval in Canada.

Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.

ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad. Varenicline tablets had annual sales of 15 mn Canadian dollar in Canada (IQVIA MAT December 2024).

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878